

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : **Fernandez et Castro et al.**  
Appln. No. : **10/591,243**  
U.S. Filing Date: **August 31, 2006**  
Title : **HIGH ALCOHOL CONTENT FOAMING  
COMPOSITIONS WITH SILICONE-BASED  
SURFACTANTS**  
Grp./A.U. : **1616**  
Examiner : **CHUI, MEI PING**  
Docket No. : **23995US01**

Commissioner for Patents  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the Applicants' duty of disclosure under 37 C.F.R. §1.56, the Applicants wish to file this Information Disclosure Statement ("IDS") under 37 CFR §1.97(c). This disclosure is also accompanied by Form PTO SB/08A.

Pursuant to 37 C.F.R. §1.97(g) and (h), the disclosure of this information in this Information Disclosure Statement shall not constitute a representation that a search for prior art was made or an admission that the information is material or that it is prior art.

1. In the Information Disclosure Statement submitted on September 27, 2011, it was disclosed that prior to the filing date of the present application, Deb

Worldwide Healthcare had developed a foamable alcohol composition comprising alcohol in a concentration higher than 60% by volume, a fluorosurfactant, water and other components.

a. More specifically, Deb developed two formulations of foamable alcohol compositions comprising alcohol (both containing ethanol and n-propanol) in a concentration higher than 60% by volume, a fluorosurfactant, water and other components. The internal designations for these products were AF286 and AF287, and they differed in the amount of n-propanol.

b. In November 2004 and thereafter, Deb made sales of the AF286 product in the United States. The AF286 product contained denatured alcohol (ethanol), water, propyl alcohol, glycerin, DEA-C8-18 perfluoroalkylethyl phosphate, butylene glycol, cocoglucoside, and glyceryl oleate.


2. Items of non-patent literature are listed on the enclosed Form PTO SB/08A. Among those items is a Communication in German from the European Patent Office for European Application No. 05825981.3 dated October 26, 2011. The relevance of the Communication is that it is for a counterpart foreign application of US Application 12/624,073, which is assigned to Deb IP Limited. A translation of the Communication is provided. The present application is assigned to Deb Worldwide Healthcare Inc., which is related to Deb IP Limited. A translation of the communication is enclosed. All of the references in the Communication were previously cited in Information Disclosure Statements submitted for the present application.

Also enclosed is a translation of the International Preliminary Report on Patentability from International Application No. PCT/EP2005/013742, which is also a

counterpart to US Application 12/624,073. It cites the same five references as the Communication from the European Patent Office.

The Commissioner is authorized to charge our Deposit Account No. 13-0017 in the name of McAndrews, Held & Malloy, Ltd. for the fee required in connection with this submission.

Respectfully submitted,

A handwritten signature in cursive script, reading "Michael B. Harlin", written in dark ink. The signature is positioned above a horizontal line.

Michael B. Harlin  
Reg. No. 43,658  
Attorney for Applicants

Date: November 10, 2011

McANDREWS, HELD & MALLOY, LTD.  
500 West Madison Street, 34th Floor  
Chicago, Illinois 60661  
Telephone (312) 775-8000  
Facsimile (312) 775-8100